LifeMD, Inc. (NASDAQ:LFMD) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. trimmed its holdings in shares of LifeMD, Inc. (NASDAQ:LFMD) by 37.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 55,204 shares of the company’s stock after selling 32,969 shares during the period. JPMorgan Chase & Co. owned approximately 0.13% of LifeMD worth $273,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of LFMD. AXQ Capital LP purchased a new position in shares of LifeMD during the fourth quarter worth $57,000. Quantbot Technologies LP acquired a new position in shares of LifeMD in the fourth quarter worth about $59,000. Prudential Financial Inc. boosted its stake in shares of LifeMD by 19.3% during the 4th quarter. Prudential Financial Inc. now owns 13,605 shares of the company’s stock worth $67,000 after acquiring an additional 2,200 shares in the last quarter. Magnus Financial Group LLC boosted its stake in shares of LifeMD by 31.1% during the 4th quarter. Magnus Financial Group LLC now owns 16,000 shares of the company’s stock worth $79,000 after acquiring an additional 3,792 shares in the last quarter. Finally, Rhumbline Advisers grew its position in shares of LifeMD by 6.1% during the 4th quarter. Rhumbline Advisers now owns 48,689 shares of the company’s stock valued at $241,000 after acquiring an additional 2,814 shares during the period. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Stock Down 2.6 %

Shares of LFMD opened at $7.25 on Friday. LifeMD, Inc. has a 52-week low of $3.99 and a 52-week high of $12.88. The stock has a market cap of $323.23 million, a PE ratio of -11.33 and a beta of 2.22. The firm’s fifty day moving average is $5.56 and its two-hundred day moving average is $5.56.

LifeMD (NASDAQ:LFMD) last released its earnings results on Monday, March 10th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02. The business had revenue of $64.26 million during the quarter, compared to analysts’ expectations of $57.43 million. As a group, research analysts anticipate that LifeMD, Inc. will post -0.56 earnings per share for the current year.

Insider Transactions at LifeMD

In other LifeMD news, CEO Justin Schreiber sold 50,000 shares of LifeMD stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $7.78, for a total value of $389,000.00. Following the sale, the chief executive officer now owns 2,575,721 shares in the company, valued at $20,039,109.38. The trade was a 1.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Jessica Friedeman sold 30,000 shares of the stock in a transaction on Friday, March 14th. The stock was sold at an average price of $5.66, for a total value of $169,800.00. Following the transaction, the chief marketing officer now owns 170,000 shares of the company’s stock, valued at approximately $962,200. This represents a 15.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 130,000 shares of company stock worth $936,300 in the last quarter. Company insiders own 15.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on LFMD shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 price target on shares of LifeMD in a research report on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of LifeMD in a research report on Wednesday. B. Riley raised shares of LifeMD to a “strong-buy” rating in a research note on Tuesday, March 11th. Finally, KeyCorp reduced their price objective on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $11.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.